Neuropsychiatry market is evolving with rising mental health awareness. Discover regional analysis, leading companies, and future market opportunities. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neuropsychiatry Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neuropsychiatry Market Revenue and Volume Forecast, by Disorder Type
8.1.1. Anxiety Disorders
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Mood Disorders
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Psychotic Disorders
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Personality Disorders
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Developmental Disorders
8.1.5.1. Market Revenue and Volume Forecast
8.1.5. Neurodegenerative Diseases
8.1.5.1. Market Revenue and Volume Forecast
9.1. Neuropsychiatry Market Revenue and Volume Forecast, by Treatment Type
9.1.1. Drug Treatments
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Psychotherapy
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Electroconvulsive Therapy (ECT)
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Transcranial Magnetic Stimulation (TMS)
9.1.4.1. Market Revenue and Volume Forecast
10.1. Neuropsychiatry Market Revenue and Volume Forecast, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intravenous (IV)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Subcutaneous
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Transdermal
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Transcranial
10.1.5.1. Market Revenue and Volume Forecast
11.1. Neuropsychiatry Market Revenue and Volume Forecast, by End-User
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Clinics
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Research Centers
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Disorder Type
12.1.2. Market Revenue and Volume Forecast, by Treatment Type
12.1.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.4. Market Revenue and Volume Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.1.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.4. Market Revenue and Volume Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Disorder Type
12.1.6.2. Market Revenue and Volume Forecast, by Treatment Type
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.4. Market Revenue and Volume Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Disorder Type
12.2.2. Market Revenue and Volume Forecast, by Treatment Type
12.2.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.4. Market Revenue and Volume Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.2.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.4. Market Revenue and Volume Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Disorder Type
12.2.6.2. Market Revenue and Volume Forecast, by Treatment Type
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.4. Market Revenue and Volume Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Disorder Type
12.2.7.2. Market Revenue and Volume Forecast, by Treatment Type
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.4. Market Revenue and Volume Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Disorder Type
12.2.8.2. Market Revenue and Volume Forecast, by Treatment Type
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.4. Market Revenue and Volume Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Disorder Type
12.3.2. Market Revenue and Volume Forecast, by Treatment Type
12.3.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.4. Market Revenue and Volume Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.3.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.4. Market Revenue and Volume Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Disorder Type
12.3.6.2. Market Revenue and Volume Forecast, by Treatment Type
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.4. Market Revenue and Volume Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Disorder Type
12.3.7.2. Market Revenue and Volume Forecast, by Treatment Type
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.4. Market Revenue and Volume Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Disorder Type
12.3.8.2. Market Revenue and Volume Forecast, by Treatment Type
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.4. Market Revenue and Volume Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Disorder Type
12.4.2. Market Revenue and Volume Forecast, by Treatment Type
12.4.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.4. Market Revenue and Volume Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.4.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.4. Market Revenue and Volume Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Disorder Type
12.4.6.2. Market Revenue and Volume Forecast, by Treatment Type
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.4. Market Revenue and Volume Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Disorder Type
12.4.7.2. Market Revenue and Volume Forecast, by Treatment Type
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.4. Market Revenue and Volume Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Disorder Type
12.4.8.2. Market Revenue and Volume Forecast, by Treatment Type
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.4. Market Revenue and Volume Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.4. Market Revenue and Volume Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Disorder Type
12.5.5.2. Market Revenue and Volume Forecast, by Treatment Type
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.4. Market Revenue and Volume Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Disorder Type
12.5.6.2. Market Revenue and Volume Forecast, by Treatment Type
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.4. Market Revenue and Volume Forecast, by End-User
13.1. Actavis Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Allergan
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. AstraZeneca
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bristol Myers Squibb
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Otsuka
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample